Subcutaneous Botulinum Toxin for Cutaneous Allodynia

Completed · Not applicable · Has a placebo group

Conditions studied: Pain

In brief

Superficial injection of Botulinum toxin has been advocated for cosmetic purposes but has also been reported to be helpful for some pain conditions. The investigators have observed prolonged profound analgesia following subcutaneous superficial injection of Botulinum Toxin Type A (BTA) in patients with certain types of neuropathic pain. The investigators propose to study if addition of BTA extends pain relief compared to placebo when injected subcutaneously into areas of cutaneous allodynia (the property that a normally non-noxious stimulus is perceived as painful).

Key facts

Study ID

NCT00725322

Run by

Stanford University

People needed

84

Starts

2007-12-01

Expected to finish

2013-03-01

Last updated by the study team

2017-10-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Any neuromuscular disorder such as myasthenia gravis, eaton lambert, muscular dystrophy
• Any ongoing legal action related to their pain
• Allergy to local anesthetics
• A current or history of any severe psychiatric disorder
• History of any adverse reaction to botulinum toxin
• History of botulism
• Untreated infection
• Coagulopathy
• Females - positive pregnancy test
• Surgery within the past 6 months at the site of the painful scar

Where it is running

• Stanford University School of Medicine — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.